Search

Leuprolide

[L13850] Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months. … [A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc.

Mebutamate

Mebutamate is a sedative and anxiolytic drug with anti-hypertensive (blood pressure lowering) effects comparable to those of other barbiturates but is only around 1/3rd the potency of secobarbital as a

Sea salt

Sea salt is a food ingredient and is often colored by adding charcoal or red clay to sometimes be referred to as “Hawaiian Sea Salt.” … Unlike sea salt, table salt usually contains an additive to prevent clumping and involves addition of iodine.

Guselkumab

Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. … IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].

Cefuroxime

Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.

PBI-1402

PBI-1402 appears to work on the PMN pathway, but its specific binding properties are not known. PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator. … However, it has been shown that when co-administered with these compounds, effects are additive, making PBI-1402 an excellent candidate for combination therapy and asserting its independent mechanism of

Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen

Enprofylline

Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and ...